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(UK). Following prohibition these drugs are still easily purchased illegally via the internet. We 
report a case of a patient who self-administered 3-Fluorophenmetrazine intravenously with 
catastrophic consequences.  Adverse effects were almost immediate with symptoms of malaise and 
tachycardia. Two days post administration he was transferred to the intensive therapy unit with 
acute kidney injury and irreversible four limb ischaemia. He required a period of renal replacement 
therapy and bilateral lower limb amputation. This case highlights the fact that new psychoactive 
substances have many unintended adverse effect which have not been previously described. 
Multiple routes of administration are used by people taking these agents including intravenously. 
Medical practitioners should always consider ingestion of new psychoactive substances in the 




Acute Kidney Injury 






Drugs previously NQRZQ DV µlegal highs¶ also UHIHUUHG WR DV µUHVHDUFK FKHPLFDOV¶, µnew 
psychoactive substances¶ (NPS) or µclub drugs¶ are chemicals that have similar effects to illegal 
drugs but until very recently remained legal to purchase in the UK. Many drugs had been made 
illegal under the misuse of Drugs Act 1971 [1]. This provision was insufficiently broad to legislate 
for the actions of some modern chemists intent on circumventing the law. The problem was that as 
soon as a new drug was identified, the Home Office placed a temporary ban on the chemical while 
it decided whether the drug should be permanently banned. By the time agents are banned chemists 
had responded by slightly altering the molecular structure making a new subtly different drug with 
similar effects. Crucially the fact that these drugs were legal does not mean that they are safe or 
approved for human use, many vendors labeled WKHPDVµQRWILWKXPDQFRQVXPSWLRQ¶. Psychoactive 
substances were made illegal in the UK in 2016 [2]. 
On 26th May 2016 the Psychoactive Substances Act came into force it making it an offence to 
µproduce, supply, offer to supply, possess with intent to supply, possess on custodial premises, 
import or export psychoactive substances; that is, any substance intended for human consumption 
that is capable of producing a psychoactive effect. The mD[LPXP VHQWHQFH ZLOO EH  \HDUV¶
LPSULVRQPHQW¶ [2].  
3-Fluorophenmetrazine (3-FPM) also known as PAL-593 was introduced onto the market via the 
internet in around 2014, since that time it has become increasingly popular. The drug won the 
VICE Netherlands 'HVLJQHU'UXJ$ZDUGV³1HZHVW'UXJRI$ZDUG´ [3]. It was legal in 
the UK until May 2016, it had already been made an illegal substance in Switzerland and Sweden. 
3-FPM is one of many phenylmorpholines designed to treat obesity or ameliorate drug dependence 
[4].   It is suggested that it has properties similar to amphetamines associated with monoamine 
release [5]. There are many unofficial reports of effects available on the internet, supplied by users. 
It seems that the majority of reported effects are as a stimulant, however there are few reports of its 
precise action [6]. We report a case of dialysis dependent acute kidney injury, four limb ischaemia 
resulting in bilateral lower limb amputation and loss of digits on his left hand, this occurred as a 
result of injection of 3-FPM intravenously. This was the first use of this drug by the patient, it was 




A 52 year old man was brought into hospital by ambulance after he was found in bed confused and 
incontinent of urine, he had a short history of worsening symptoms over two days. The patient was 
a known intravenous drug user with a previous history of infective endocarditis. He had a bovine 
mitral valve replacement performed at a central London hospital the previous year. He was 
reported to have injected a drug called 3-FPM, the drug was purchased online three days prior to 
presentation. He denied any recent or co-use of other non-prescription drugs he had discontinued 
MPA some days prior to administration because he had been unable to obtain it following 
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prohibition. He had purchased this experimental drug as an alternative to MPA which he had been 
using regularly. The drug was bought in powdered/crystalline form (Figure 1). He completely 
dissolved in water without any residue and then injected into his arm. On the same day, after 
injecting the drug he started to develop flu-like symptoms feeling feverish with general malaise 
and tachycardia.  Over the next two days the symptoms worsened, he started to develop symptoms 
of shortness of breath, a productive cough of white sputum, central chest pain, fever with rigors 
and multiple episodes of diarrhoea and vomiting. He also complained of cold lower limbs with 
reduced sensation in both legs.  
He lived alone and was previously completely self-caring with a full time job. He had a long term 
partner of 10 years. He was a lifelong smoker until November 2014. There was no history of 
alcohol ingestion.  
He had previously been diagnosed with attention deficit hyperactivity disorder (ADHD) and 
depression. In 2014 he developed cord compression at C1/C2 secondary to an abscess at the same 
time he was diagnosed with endocarditis. He had made a full recovery following treatment for 
endocarditis which included a long course of antibiotics and a bovine valve replacement. There 
was no history of chronic kidney disease, diabetes or hypertension. 
On admission the patient was treated for suspected sepsis and acute kidney injury (AKI) with 
intravenous fluids and broad spectrum antibiotics.  
He subsequently developed atrial fibrillation with a rapid ventricular rate and was treated with 
amiodarone. After one day his condition deteriorated and he was transferred into Intensive 
Therapy Unit, he was hypotensive (BP 95/50mmHg), respiratory rate 31, pulse  rate 97 bpm and 
temperature 35·2 degrees Celsius.  All four limbs became rapidly ischaemic (Figure 2.) he also had 
widespread livedo reticularis.  
Urinalysis was not performed on admission because the patient was anuric, a urethral catheter was 
passed. His urine output started to improve after 20 days at that time he did not have significant 
proteinuria, he had invisible haematuria as expected due to urinary tract instrumentation. 
Transthoracic echocardiography was performed, there was no evidence of vegetation or significant 
change in valvular function compared to the previous studies. Bloods showed C3 0·67 g/L(0·75-
1·45), C4 0·11 g/L(0·14-0·54), C-reactive protein 188 mg/L, Creatinine Kinase was 187U/L 
repeated blood cultures showed no significant bacterial growth, ANA, ANCA and DS-DNA were 
all negative. Clotting studies, including fibrinogen and thrombin time were normal. Analysis of the 
drug demonstrated 3-FPM only (City Hospital Birmingham), at the time of the analysis it was 
noted that the package was mislabelled as containing 1-propionyl-lysergic acid diethylamide 
which it did not. 
The patient was started on continuous veno-venous haemofiltration to manage his acute kidney 
injury he required renal replacement therapy for 26 days. He received broad spectrum 
antimicrobials to cover gram positive, and negative organisms as well as antifungals. In addition 
he was treated with epoprostenol sodium intravenously to try and improve peripheral blood flow, 
he did not receive glucocorticoids during the course of his illness. His respiratory function was 
supported with hi-flow oxygen, he did not require mechanical ventilation.  
He was reviewed regularly by the vascular surgical team. Initially he was too unstable to undergo 
surgery, however after two weeks he was taken to theatre for a below knee amputation of his right 
leg, a week later he underwent a left below knee amputation. Four weeks following admission his 
renal function started to recover and he no longer required renal replacement therapy. His 
ischaemic hands remained a problem on the ward, however his right hand appeared to have 
completely resolved with only severe necrosis in his left fourth metatarsal and tips of his other 




The combination of limb ischaemia, livedo reticularis, fever and raised inflammatory markers 
clearly raises the possibility of systemic inflammatory response syndrome secondary to sepsis, 
with or without disseminated intravascular coagulation (DIC), his CRP and marginally low 
complement levels would have supported this, there was no evidence of DIC based on his 
laboratory tests. His blood cultures were repeatedly negative although culture negative sepsis 
occurs in up to 40% of cases [7]. The differential diagnosis also includes cryoglobulinaemia, intra-
arterial injection, cholesterol embolization, purpura fulminans and anti-phospholipid syndrome.  
His symptoms may have been a manifestation of systemic vasculitis secondary to systemic lupus 
erythematosus, rheumatoid arthritis or dermatomyositis however clinical and serological evidence 
for these disorders was lacking. There have been some unconfirmed reports of vasculitis associated 
with the use of 3-FPM. Intra-arterial injection remains a possibility but would not explain four 
limb ischaemia and widespread livedo. Cholesterol embolization is a possible explanation for the 
development of critical limb ischaemia, livedo and acute kidney injury, against this differential is a 
normal eosinophil count and the recovery of renal function. Patients with cholesterol emboli may 
recover renal function but in the context of such catastrophic limb effects the mortality rate is 
reported as approximately 90%. Purpura fulminans has a similar presentation to this case, it is 
possible that the patient developed this as a direct result of the chemical agent, against this 
differential is the fact that the patient did not develop laboratory features of DIC. The differential 
diagnosis also includes infective endocarditis leading to AKI, sepsis and limb ischaemia, 
transthoracic echocardiography does not exclude a vegetation particularly in the presence of a 
prosthetic heart valve. The course of his illness including the stability of cardiac function and full 
recovery of renal function (recovery GFR 60ml/min/1.73m2) are against this as the underlying 
cause. )LQDOO\%XHUJHU¶VGLVHDVH (thromboangiitis obliterans) may have been an underlying cause 
of his four limb ischaemia however in this case the clinical course was very short which is not in 
keeping with the usual presentation of this disorder.  
In this case the patient developed irreversible lower limb ischaemia resulting in the need for 
amputation in association with acute kidney injury, which recovered. This suggests that the 




Another possibility is that the mechanism of injury was different, it is possible that the 
administration of the drug resulted in a direct nephrotoxic effect or tubulointerstitial nephritis. 
We suggest that the injected agent which is said to be amphetamine like in its action caused 
significant widespread vasoconstriction with or without concomitant infection resulting in 
widespread ischaemia out of proportion to the clinical feature of sepsis. The underlying cause of 
both critical limb ischaemia and acute kidney injury are likely to be the same namely ischaemia, 
however recovery from acute tubular necrosis is known to occur even in the context of a 
significant period of ischaemia. Websites reporting adverse effects of this agent when taken orally 
for recreational purposes describe cold peripheries as a common adverse effect, this supports the 
hypothesis that the drug when injected resulted in four limb ischaemia. The clinical features are in 
keeping with adverse events associated with the use of this drug in the STRIDA project in Sweden. 
Backberg et al reported 19 cases of people testing positive for 3-FPM, 5 of which were reported as 
having severe intoxication, prominent clinical signs were tachycardia (47%), depressed 
consciousness (42%), agitation/anxiety (37%), delirium (37%), dilated pupils (26%), and seizures 
(16%). The authors did note that all of the patients tested positive for other psychoactive 
compounds thus making it difficult definitely attribute adverse effects to 3-FPM alone [8]. Our 
patient administered 3-FPM intravenously, there are no studies on the relative bioavailability of 
oral and intravenous administration. The metabolism of 3-FPM is poorly understood, it has a 
chemical structure similar to phenmetrazine which was marketed as an anorectic but is no longer 
available or legal. Phenmetrazine has a half-life of approximately 8 hours after oral administration. 
Metabolism of the drug is primarily hepatic (via CYP3A and CYP2D6), it is resistant to 
metabolism by monoamine oxidase. Metabolism involves deamination to para-
hydroxyamphetamine and phenylacetone. It is likely that the effects would be enhanced when 
administered intravenously due to avoidance of first pass metabolism and poor absorption via the 
GI tract.  
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Figure 1. Packaging and Powder labelled as 3-Fluorophenmetrazine 
 
Figure 1. Packaging and presentation of 3-Fluorophenmetrazine as a drug for reference use only 
and not for human consumption sold prior to Psychoactive Substances Act 2016. 
Figure 2. Ischaemic Limbs, Livedo Reticularis. 
 
Figure 2. Photographs taken day 3 post admission with the consent of the patient demonstrating 
widespread livedo reticularis on the trunk and limbs and critical ischaemia of the lower limbs and 
fingers. 
 
 
 
 
 
 
 
